Agreed t4p this raising at 1.8c although slightly lower then you...

Agreed t4p this raising at 1.8c although slightly lower then you and i myself would have liked will put ANP in s strong position going forward to both start ATL1103 trials and also give them more leverage in their ongoing due diligence with this pharma or any other that comes along. Yes i would have also liked 2c but hey as with my cornerstone investor post and my example of PRR in 2009 who gave Laurence Freedmon 1.5 mill $$ worth of stock at 2.6c when PRR hit 11c 7 days earlier and traded between 6>8c through the week prior to that placement sometimes a company must give a little to get a significant investor on board. At the time PRR did that placement i was annoyed but understood that sometimes with these bios getting a bigger name on board as a holder can lead to increased exposure through that larger investor.

I must also say that your taking of the ANP board and their background in comparison to CVI's is yes like chalk and cheese. I have met the ANP board at the AGM and have spoken to Mark on numerous occasions and they are trying to get ANP back on track with their ATL range and are looking to increase shareholder value across their range of drugs with ATL1103 the star but not forgetting that getting ATL1102 back up and running with the Chinese is a significant step in getting major value for shareholders. Dont forget ATL1102 when gets back up and running with MS trials is heading into late stage phs2b/3 trials and a similar position to where PRR is with CVAC. As stated in the Chinese announcement though the difference here is that PRR must fund their phs2b/3 CVAC trials but the Chinese will be funding the ATL1102 trials across all applications. The market still doesn't see value in this but will when the deal is fully signed off prior to July. I expect that that will add significant amounts to the market cap of ANP.